Global leader in liquid nitrogen storage systems expected to support growth, diversify revenue and reduce evo® manufacturing costs Preliminary 2020 revenue guidance of $50 - $56 Million Conference ...
CEO Rod de Greef highlighted 2024 as a pivotal year for BioLife, marked by strategic portfolio reshaping, divestitures of non-core product lines, and consistent growth in the Cell Processing platform.
Merit Medical Systems, Inc. has announced the acquisition of Biolife Delaware, L.L.C., which produces hemostatic devices under the StatSeal and WoundSeal brands. This strategic move is expected to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback